Navigation Links
Amyotrophic Lateral Sclerosis Association honors Dr. Robert Baloh, M.D.
Date:4/27/2012

LOS ANGELES (April 27, 2012) Robert H. Baloh, MD, PhD, director of Cedars-Sinai Medical Center's Neuromuscular Division, has received the ALS Association Golden West Chapter Commitment to a Cure Award.

Baloh, one of the top doctors and research scientists treating and studying amyotrophic lateral sclerosis (also known as Lou Gehrig's disease), has published groundbreaking discoveries in genetics and molecular biology and is the principal investigator of five projects examining the molecular and cellular basis of ALS and other neuromuscular disorders.

He joined Cedars-Sinai in early 2012 to create one of the most comprehensive ALS treatment and research teams in California, joining Clive Svendsen, PhD, director of the Regenerative Medicine Institute, and Patrick D. Lyden, MD, chair of the Department of Neurology and the Carmen and Louis Warschaw Chair in Neurology.

"I am very honored that the ALS Association chose to recognize our efforts toward developing a cure for ALS. I especially want to acknowledge our patients where ALS runs in their family, whose willingness to work closely with us has been key to our success," Baloh said.

Svendsen said, "We are very proud that Dr. Baloh received this recognition from the ALS Association. He is an outstanding scientist and clinician devoted to solving the mysteries of ALS."

Baloh's research group was one of the first to discover that mutations in the TDP-43 gene cause inherited forms of ALS and frontotemporal lobar degeneration, a type of dementia that can accompany ALS. He also led studies that in 2009 produced the first mouse model of ALS based on the TDP-43 gene. The first new ALS mouse model in 14 years, it is employed by researchers worldwide to study the disease.

Baloh earned his PhD and MD degrees at Washington University School of Medicine in St. Louis and is board certified in both neurology and neuromuscular medicine. Two of his current research projects are funded by the National Institutes of Health/National Institute of Neurological Disorders and Stroke and others are supported by grants from the Muscular Dystrophy Association and Burroughs Wellcome Foundation.  

Even as Baloh and his colleagues seek cures, they work to improve their patients' quality of life. Cedars-Sinai's multidisciplinary ALS clinic recently became the first West Coast site and one of only three nationwide providing an implanted breathing-assist device for ALS patients suffering chronic hypoventilation, the inability to take enough air into the lungs. The device can be used in a hospital, at a rehabilitation center or at home, and unlike an external ventilator, the system is silent.


'/>"/>

Contact: Sandy Van
sandy@prpacific.com
808-526-1708
Cedars-Sinai Medical Center
Source:Eurekalert

Related medicine news :

1. Contralateral prophylactic mastectomy offers limited gains for breast cancer patients
2. War on cancer produces collateral damage to the heart
3. Gay mens bilateral brains better at remembering faces: York U study
4. Kessler Foundation scientist awarded $554,000 for multiple sclerosis employment research
5. Fish Oil Supplements Wont Help in Multiple Sclerosis: Study
6. Experimental Pill for Multiple Sclerosis Shows Promise
7. Experimental Pill May Ease Multiple Sclerosis Disability
8. Diabetes drug halts atherosclerosis progression in HIV-infected patients
9. Researchers discover new culprit in atherosclerosis
10. Multiple Sclerosis May Cause Changes in Thalamus: Study
11. Beneficial or not beneficial: that is the question for IL-1 inhibition in atherosclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
Breaking Medicine Technology: